Divi's Laboratories Limited
NSE: DIVISLAB BSE: DIVISLAB
NSE
6,565.50
-21.50 (-0.33%)
Prev Close
6587
Open Price
6600
Volume
286,780
Today Low / High
6548.5 / 6627.5
52 WK Low / High
4955 / 7071.5
Range
6,237 - 6,894
BSE
6,561.10
-32.25 (-0.49%)
Prev Close
6593.35
Open Price
6267.35
Volume
12,560
Today Low / High
6267.35 / 6624
52 WK Low / High
4941.7 / 7077.7
Range
6,233 - 6,889
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 6565.5 (target range: 6,237 - 6,894), reflecting a change of -21.5 (-0.3264%). On the BSE, it is listed at 6561.1 (target range: 6,233 - 6,889), showing a change of -32.25 (-0.48913%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
23 Oct
6,600.00
-0.52%
21 Oct
6,648.00
-0.92%
20 Oct
6,645.00
-0.62%
17 Oct
6,580.00
0.63%
16 Oct
6,573.00
0.42%
15 Oct
6,580.00
-0.11%
14 Oct
6,570.00
-0.14%
13 Oct
6,465.50
1.40%
10 Oct
6,132.50
5.58%
09 Oct
6,149.00
-0.28%
08 Oct
6,115.00
0.09%
07 Oct
5,860.00
4.17%
06 Oct
5,885.00
-0.99%
03 Oct
5,759.50
1.85%
01 Oct
5,692.50
0.31%
30 Sep
5,713.50
-0.42%
29 Sep
5,717.00
-0.34%
26 Sep
5,824.00
-2.31%
25 Sep
5,985.00
-1.47%
Divi's Laboratories Limited Graph
Divi's Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Divi's Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 6,565.50, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 6,561.10 | 6,626.71 | 5,964.04 - 7,289.38 |
| 6,692.32 | 5,353.86 - 8,030.79 | ||
| 6,757.93 | 4,730.55 - 8,785.31 | ||
| Bearish Scenario | 6,561.10 | 6,495.49 | 5,845.94 - 7,145.04 |
| 6,429.88 | 5,143.90 - 7,715.85 | ||
| 6,364.27 | 4,454.99 - 8,273.55 |
Overview of Divi's Laboratories Limited
ISIN
INE361B01024
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
440,985
Market Cap
1,742,939,424,486
Last Dividend
30
Official Website
IPO Date
2003-03-12
DCF Diff
-5,141.54
DCF
11,707
Financial Ratios Every Investor Needs
Stock Dividend of DIVISLAB
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-25 | July 25, 25 | 30 | 30 | 2025-07-25 | 2025-08-16 | |
| 2024-08-02 | August 02, 24 | 30 | 30 | 2024-08-02 | 2024-09-11 | |
| 2023-08-11 | August 11, 23 | 30 | 30 | 2023-08-11 | 2023-09-27 | |
| 2022-08-11 | August 11, 22 | 30 | 30 | 2022-08-12 | 2022-09-21 | |
| 2021-08-17 | August 17, 21 | 20 | 20 | 2021-08-19 | 2021-09-29 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 9,358.00 Cr | 6,167.00 Cr | 3,191.00 Cr | 0.3410 | 80.00 Cr | 143.00 Cr | 2,638.00 Cr | 2,191.00 Cr | 82.53 | 3,321.00 Cr | 0.2341 |
| 2024-03-31 | 7,796.00 Cr | 3,269.00 Cr | 4,527.00 Cr | 0.5807 | 79.00 Cr | 125.00 Cr | 1,952.00 Cr | 1,600.00 Cr | 60.27 | 2,543.00 Cr | 0.2052 |
| 2023-03-31 | 7,748.81 Cr | 5,195.19 Cr | 4,487.00 Cr | 0.5791 | 33.00 Cr | 126.00 Cr | 2,062.21 Cr | 1,824.00 Cr | 68.69 | 2,713.77 Cr | 0.2354 |
| 2022-03-31 | 8,799.23 Cr | 3,091.88 Cr | 5,707.35 Cr | 0.6486 | 54.95 Cr | 108.59 Cr | 3,573.77 Cr | 2,960.45 Cr | 111.52 | 3,997.00 Cr | 0.3364 |
| 2021-03-31 | 6,858.34 Cr | 2,324.08 Cr | 4,534.26 Cr | 0.6611 | 51.01 Cr | 83.14 Cr | 2,615.99 Cr | 1,984.29 Cr | 74.75 | 2,923.72 Cr | 0.2893 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 432.00 Cr | 16,947.00 Cr | 1,978.00 Cr | 14,969.0000 Cr | 4.00 Cr | -428.00 Cr | 3,323.00 Cr | 6,698.00 Cr | 40.00 Cr | 0.00 Cr | 74.00 Cr | 1,452.0000 Cr |
| 2024-03-31 | 363.00 Cr | 15,470.00 Cr | 1,899.00 Cr | 13,571.0000 Cr | 3.00 Cr | -360.00 Cr | 3,184.00 Cr | 5,513.00 Cr | 34.00 Cr | 0.00 Cr | 82.00 Cr | 1,278.0000 Cr |
| 2023-03-31 | 170.00 Cr | 14,439.00 Cr | 1,672.00 Cr | 12,767.0900 Cr | 4.00 Cr | -166.00 Cr | 3,000.00 Cr | 4,929.00 Cr | 0.00 Cr | 0.00 Cr | -3,837.86 Cr | 1,101.0000 Cr |
| 2022-03-31 | 1,214.76 Cr | 13,374.71 Cr | 1,646.53 Cr | 11,728.1800 Cr | 3.69 Cr | -1,211.07 Cr | 2,828.62 Cr | 4,787.49 Cr | 16.63 Cr | 0.00 Cr | 72.01 Cr | 1,195.5500 Cr |
| 2021-03-31 | 2,030.32 Cr | 10,774.07 Cr | 1,479.46 Cr | 9,294.6100 Cr | 4.83 Cr | -2,025.49 Cr | 2,145.23 Cr | 4,409.54 Cr | 0.00 Cr | 0.00 Cr | -53.18 Cr | 1,112.4600 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,946.0000 Cr | -1,099.0000 Cr | -797.0000 Cr | 508.0000 Cr | 61.0000 Cr | 432.0000 Cr | -1,438.0000 Cr | 2,191.0000 Cr | -1.0000 Cr | -796.0000 Cr | -52.0000 Cr |
| 2024-03-31 | 1,261.0000 Cr | -269.0000 Cr | -799.0000 Cr | 258.0000 Cr | 193.0000 Cr | 363.0000 Cr | -1,003.0000 Cr | 1,600.0000 Cr | -1.0000 Cr | -796.0000 Cr | -184.0000 Cr |
| 2023-03-31 | 2,459.0000 Cr | -2,707.0000 Cr | -796.8400 Cr | 1,986.0000 Cr | -1,045.0000 Cr | 170.0000 Cr | -473.0200 Cr | 2,368.6300 Cr | -1.0000 Cr | -796.4100 Cr | -171.7900 Cr |
| 2022-03-31 | 1,911.8000 Cr | -2,194.9200 Cr | -532.4400 Cr | 1,198.6000 Cr | -815.5600 Cr | 1,214.7600 Cr | -713.2000 Cr | 3,683.5000 Cr | -0.3500 Cr | -530.9400 Cr | -683.3900 Cr |
| 2021-03-31 | 1,946.9300 Cr | 75.1300 Cr | -34.8900 Cr | 1,036.7400 Cr | 1,987.1700 Cr | 2,030.3200 Cr | -910.1900 Cr | 2,666.0400 Cr | -33.2800 Cr | 0.0000 Cr | -281.3700 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 2,410.00 Cr | 1,408.00 Cr | 1,002.00 Cr | 0.4158 | 617.00 Cr | 545.00 Cr | 20.53 | 848.00 Cr | 0.2261 |
| 2025-03-31 | 2,585.00 Cr | 981.00 Cr | 1,604.00 Cr | 0.6205 | 779.00 Cr | 662.00 Cr | 24.95 | 972.00 Cr | 0.2561 |
| 2024-12-31 | 2,319.00 Cr | 922.00 Cr | 1,397.00 Cr | 0.6024 | 644.00 Cr | 589.00 Cr | 22.20 | 825.00 Cr | 0.2540 |
| 2024-09-30 | 2,338.00 Cr | 969.00 Cr | 1,369.00 Cr | 0.5855 | 617.00 Cr | 510.00 Cr | 19.20 | 822.00 Cr | 0.2181 |
| 2024-06-30 | 2,118.00 Cr | 1,242.00 Cr | 876.00 Cr | 0.4136 | 526.00 Cr | 430.00 Cr | 16.20 | 701.00 Cr | 0.2030 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 3,527.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -14,969.00 Cr |
| 2025-03-31 | 415.00 Cr | 3,124.00 Cr | 3,731.00 Cr | 2,731.00 Cr | 3,236.00 Cr | 10,081.00 Cr | 6,460.00 Cr | 16,932.00 Cr | 1,963.00 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 3,602.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -13,717.00 Cr |
| 2024-09-30 | 38.00 Cr | 3,570.00 Cr | 3,608.00 Cr | 2,181.00 Cr | 3,145.00 Cr | 9,341.00 Cr | 5,970.00 Cr | 15,586.00 Cr | 1,869.00 Cr |
| 2024-06-30 | -3,698.00 Cr | 7,396.00 Cr | 3,698.00 Cr | 0.00 Cr | 0.00 Cr | 3,698.00 Cr | 0.00 Cr | 0.00 Cr | -13,571.00 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 545.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 662.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 589.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 510.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 430.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2015-09-23 | September 23, 15 | 2:1 |
| 2009-07-30 | July 30, 09 | 2:1 |
| 2007-08-03 | August 03, 07 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,689.90 | ₹4,054,630,043,295.00 | ₹2,686,980.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,565.50 | ₹1,742,939,424,486.00 | ₹286,780.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,614.10 | ₹1,223,174,074,500.00 | ₹240,710.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,279.40 | ₹1,064,937,056,650.00 | ₹1,991,211.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹1,009.00 | ₹1,015,285,627,049.00 | ₹693,669.00 |
| Mankind Pharma Limited | MANKIND | ₹2,451.00 | ₹1,011,671,058,990.00 | ₹170,162.00 |
| Lupin Limited | LUPIN | ₹1,939.80 | ₹886,018,912,346.00 | ₹803,342.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,534.00 | ₹661,672,710,000.00 | ₹49,489.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,099.10 | ₹638,359,063,839.00 | ₹885,643.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,850.60 | ₹522,240,817,135.00 | ₹668,277.00 |
| Laurus Labs Limited | LAURUSLABS | ₹934.40 | ₹504,412,385,626.00 | ₹4,120,655.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹886.65 | ₹339,203,154,681.00 | ₹159,159.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,276.80 | ₹323,929,545,542.00 | ₹122,915.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,414.50 | ₹301,657,064,148.00 | ₹77,009.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,708.80 | ₹267,591,653,203.00 | ₹156,241.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,301.00 | ₹232,525,000,000.00 | ₹4,288.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,358.80 | ₹220,784,347,599.00 | ₹213,204.00 |
| Eris Lifesciences Limited | ERIS | ₹1,589.60 | ₹216,525,065,438.00 | ₹52,200.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹16,198.00 | ₹207,818,542,022.00 | ₹27,722.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹921.55 | ₹181,142,746,922.00 | ₹59,767.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,127.10 | ₹178,702,588,646.00 | ₹197,287.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,023.00 | ₹153,771,661,008.00 | ₹52,129.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹834.20 | ₹149,413,453,554.00 | ₹351,701.00 |
| Granules India Limited | GRANULES | ₹557.15 | ₹135,202,875,119.00 | ₹1,238,648.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,116.00 | ₹101,521,820,312.00 | ₹6,525.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹838.30 | ₹75,977,617,913.00 | ₹67,340.00 |
| Strides Pharma Science Limited | STAR | ₹816.45 | ₹75,254,412,345.00 | ₹355,005.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹366.20 | ₹71,622,061,019.00 | ₹251,321.00 |
| FDC Limited | FDC | ₹437.80 | ₹71,278,254,775.00 | ₹174,794.00 |
| Sequent Scientific Limited | SEQUENT | ₹203.62 | ₹50,887,254,313.00 | ₹699,579.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹507.75 | ₹46,342,342,500.00 | ₹81,325.00 |
| Innova Captab Limited | INNOVACAP | ₹805.00 | ₹46,066,067,845.00 | ₹31,124.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹131.99 | ₹42,833,604,400.00 | ₹202,778.00 |
| Suven Life Sciences Limited | SUVEN | ₹193.93 | ₹42,284,632,369.00 | ₹197,754.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,345.10 | ₹38,785,644,077.00 | ₹10,698.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹725.55 | ₹36,799,246,633.00 | ₹88,171.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹344.35 | ₹34,532,280,941.00 | ₹32,045.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹467.20 | ₹32,893,566,400.00 | ₹9,980.00 |
| Hikal Limited | HIKAL | ₹244.15 | ₹30,103,878,113.00 | ₹148,629.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹95.22 | ₹27,949,689,502.00 | ₹1,002,038.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹49.04 | ₹26,871,649,399.00 | ₹1,247,513.00 |
| Indoco Remedies Limited | INDOCO | ₹282.30 | ₹26,017,277,552.00 | ₹66,219.00 |
| Alembic Limited | ALEMBICLTD | ₹100.91 | ₹25,911,854,263.00 | ₹202,140.00 |
Key Executives
Whole-time Director, Chief Control Officer & Director of Commercial
Ms. Nilima Prasad Divi
Gender: female
Year Born: 1983
Chief Information Officer
Mr. Manoranjan Jasti
Gender: male
Year Born:
MD & Executive Director
Dr. Murali Krishna Prasad Divi M. Pharm, Ph.D.
Gender: Not Specified
Year Born: 1951
Chief Executive Officer & Whole-Time Director
Dr. Kiran Satchandra Divi B. Pharm., M.Pharm
Gender: Not Specified
Year Born: 1976
Vice President of Sales, Marketing & Logistics
Mr. Satya Prakash Divi B.Tech (Mech), MBA, MS (CIS)
Gender: male
Year Born: 1977
Global Quality Head
Mr. Y. T. S. Prasad B.E.
Gender: male
Year Born: 1969
Whole-Time Director (Manufacturing)
Dr. Devendra Rao Sureddy M.Sc.
Gender: Not Specified
Year Born: 1962
Executive Director
Mr. Venkata Ramana Nimmagadda B.Sc.(Chem)
Gender: male
Year Born: 1958
Chief Financial Officer
Mr. L. Kishore Babu B.Com, FCMA, FICWA
Gender: male
Year Born: 1952
Company Secretary & Compliance Officer
Mr. M. Satish Choudhury
Gender: male
Year Born:
FAQs about Divi's Laboratories Limited
Who is the CEO of the company?
The CEO is Kiran Satchandra Divi B. Pharm., M.Pharm.
What is the current market price of the stock?
The current price is ₹6,565.50.
What is the 52-week price range?
The range is ₹4955-7071.5.
What is the market capitalization of the company?
The market capitalization is ₹174,293.94 crores.
What is the dividend yield?
The dividend yield is 0.46%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 75.58.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Divi's Laboratories Limited (ISIN: INE361B01024) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹174,293.94 crores and an average daily volume of 440,985 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹30.